5Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro- A -type natriuretic peptide, mid -regional pro -a- drenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail, 2007, 13(1):42-49.
6Oghlakian G, Klapholz M. Vasopressin and vasopressin re- ceptor antagonists in heart failure. Cardiol Rev, 2009, 17 (1):10-15.
7Khan SQ, Dhillon OS, O'Brien R J, et al. C-terminal prova- sopressin (copeptin) as a novel and prognostic marker in a- cute myocardial infarction: Leicester Acute Myocardial In- farction Peptide (LAMP) study. Circulation, 2007, 115(16): 2103-2110.
8Staub D, Morgenthaler NG, Buser C, et al. Use of copeptin in the detection of myocardial ischemia. Clin Chim Acta, 2009, 399(1-2):69-73.
9Ichiki T, Boerrigter G, Huntley BK, et al. Differential ex- pression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol, 2013, 304 (2): R102-109.
10Calvin AD, Somers VK, van der Walt C, et al. Relation of natriuretic peptide concentrations to central sleep apnea in patients with heart failure. Chest, 2011,140(6):1517-1523.
1Guyatt GH,Sullivan MJ,Thompson PJ,et al.The 6 minute walk test:a new measure of exercise capacity in patients with chronic heart failure[J].Can Med Assoc J,1985,132(4):919-923.
2Seino Y,Momomura S,Kihara Y,et al.Effects of adaptive servoventilation therapy on cardiac function and remodeling in patients with chronic heart failure(SAVIOR-C):Study protocol for a randomized controlled trial[J].Trials,2015,16(1):530-532.
